Heura Domènech

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

R. Dienstmann, O. Díez, S. Gutiérrez‐Enríquez, 2024, Genome medicine.